Home > Boards > US Listed > Biotechs > Atossa Genetics, Inc. (ATOS)

Offering will come. They'll be outta cash by

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
S3lfMade Member Profile
 
Followed By 318
Posts 24,388
Boards Moderated 0
Alias Born 04/10/09
160x600 placeholder
Atossa Genetics to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment Conference GlobeNewswire Inc. - 9/6/2019 8:30:00 AM
Atossa Genetics Announces Completion of Enrollment and Dosing in Phase 1 Clinical Trial of New Proprietary Modified-Release O... GlobeNewswire Inc. - 9/3/2019 8:00:00 AM
Atossa Genetics Announces Second Quarter 2019 Financial Results and Provides Company Update GlobeNewswire Inc. - 8/13/2019 1:26:06 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/13/2019 8:33:56 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/13/2019 8:32:21 AM
Atossa Genetics CEO Steven Quay Gives Tedx Talk At University of Washington Regarding the the Relationship of Dense Breast Ti... GlobeNewswire Inc. - 7/30/2019 8:30:00 AM
Atossa Genetics Provides Information on FDA Expanded Access Policy and Requests GlobeNewswire Inc. - 7/17/2019 8:30:00 AM
Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Phase 1 Clinical Trial Initiated GlobeNewswire Inc. - 7/11/2019 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/27/2019 12:49:44 PM
Atossa Genetics’ Preliminary Phase 2 Study Achieves Primary Endpoint: Topical Endoxifen Rapidly Reduces Breast Density GlobeNewswire Inc. - 6/27/2019 8:00:00 AM
Atossa Genetics to Present at the 9th Annual LD Micro Invitational on June 4, 2019 GlobeNewswire Inc. - 5/30/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/17/2019 4:32:45 PM
Atossa Genetics Announces First Quarter 2019 Financial Results and Provides Company Update GlobeNewswire Inc. - 5/13/2019 5:21:57 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/13/2019 4:35:15 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/13/2019 4:32:57 PM
Atossa Genetics Provides Clinical Update at the 4th Annual Precision: Breast Cancer World R&D Summit GlobeNewswire Inc. - 4/25/2019 12:00:00 PM
Atossa Genetics to Present at the 4th Annual Precision: Breast Cancer World R&D Summit April 25, 2019 GlobeNewswire Inc. - 4/22/2019 8:30:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/12/2019 12:02:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/28/2019 4:34:52 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/28/2019 4:34:51 PM
Atossa Genetics Announces Year End 2018 Financial Results and Provides Company Update GlobeNewswire Inc. - 3/28/2019 4:30:00 PM
Atossa Genetics Announces Institutional Review Board Approval of Oral Endoxifen as Post-Mastectomy Treatment for a U.S. Breas... GlobeNewswire Inc. - 3/26/2019 8:30:00 AM
Atossa Genetics Announces Receipt of $10 Million GlobeNewswire Inc. - 3/18/2019 8:30:00 AM
Atossa Genetics Announces FDA Approval of Oral Endoxifen for “Expanded Access” as Post-Mastectomy Treatment for a U.S. Br... GlobeNewswire Inc. - 3/14/2019 8:30:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/8/2019 1:32:19 PM
S3lfMade   Thursday, 03/14/19 04:32:55 PM
Re: None
Post # of 2984 
Offering will come. They'll be outta cash by the end of next quarter. That's why so much dilution today

Thoughts expressed by me should not be used as buy or sell advice. Play at your own risk!!
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist